U.S. uses option for additonal Biocryst Rapivab for Strategic National Stockpile

The U.S. Department of Health and Human Services (HHS) has exercised its option to purchase an additional 10,000 doses of BioCryst Pharmaceuticals’ (NASDAQ:BCRX) approved antiviral influenza therapy, RAPIVAB (peramivir injection).

With the exercise of the second option, BioCryst plans to deliver a total of 20,000 doses of RAPIVAB, which will add ~$14M of non-dilutive capital to the company, by the end of 2019.

The RAPIVAB purchase by the HHS Office will supply the Strategic National Stockpile.

https://seekingalpha.com/news/3502001-u-s-government-exercises-option-additonal-rapivab-strategic-national-stockpile